Mechanistic Study of the Effect of ET-1 SNPs in Coronary Microvascular Disease
Latest Information Update: 07 Apr 2023
At a glance
- Drugs Zibotentan (Primary)
- Indications Syndrome X
- Focus Therapeutic Use
- Acronyms SURPRIZE
- 01 Apr 2023 Status changed from recruiting to completed.
- 02 Oct 2022 Planned End Date changed from 1 Feb 2023 to 5 Aug 2023.
- 02 Oct 2022 Planned primary completion date changed from 5 Aug 2022 to 5 Mar 2023.